Abstract
Background
17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin that binds to and inhibits the Hsp90 family of molecular chaperones leading to the proteasomal degradation of client proteins critical in malignant cell proliferation and survival. We have undertaken a Phase 1 trial of CNF1010, an oil-in-water nanoemulsion of 17-AAG.
Methods
Patients with advanced solid tumors and adequate organ functions received CNF1010 by 1-h intravenous (IV) infusion, twice a week, 3 out of 4 weeks. Doses were escalated sequentially in single-patient (6 and 12 mg/m2/day) and three-to-six-patient (≥25 mg/m2/day) cohorts according to a modified Fibonacci’s schema. Plasma pharmacokinetic (PK) profiles and biomarkers, including Hsp70 in PBMCs, HER-2 extracellular domain, and IGFBP2 in plasma, were performed.
Results
Thirty-five patients were treated at doses ranging from 6 to 225 mg/m2. A total of 10 DLTs in nine patients (2 events of fatigue, 83 and 175 mg/m2; shock, abdominal pain, ALT increased, increased transaminases, and pain in extremity at 175 mg/m2; extremity pain, atrial fibrillation, and metabolic encephalopathy at 225 mg/m2) were noted. The PK profile of 17-AAG after the first dose appeared to be linear up to 175 mg/m2, with a dose-proportional increase in C max and AUC0–inf. Hsp70 induction in PBMCs and inhibition of serum HER-2 neu extracellular domain indicated biological effects of CNF1010 at doses >83 mg/m2.
Conclusion
The maximum tolerated dose was not formally established. Hsp70 induction in PBMCs and inhibition of serum HER-2 neu extracellular domain indicated biological effects. The CNF1010 clinical program is no longer being pursued due to the toxicity profile of the drug and the development of second-generation Hsp90 molecules.
Similar content being viewed by others
References
Karapanagiotou EM, Syrigos K, Saif MW (2009) Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs 18(2):161–174
Young JC, Moarefi I, Hartl FU (2001) Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154(2):267–273
Sausville EA (2001) Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 7:2155–2158
Ferrarini M et al (1992) Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51:613–619
Schneider C et al (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci 93:14536–14541
Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2(1):3–24
Takimoto CH, Diggikar S (2002) Heat shock protein and proteasome targeting agents. Hematol Oncol Clin N Am 16:1269–1285
Banerji U, Judson I, Workman P (2003) The clinical applications of heat shock protein inhibitors in cancer present and future. Curr Cancer Drug Targets 3:385–390
Supko JG et al (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305–315
Kamal A et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407
Page J et al (1997) Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats. Proc Am Assoc Cancer Res 38
Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharamcol 42:273–279
Kelland LR et al (1999) DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 91:1940–1949
Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15:419–424
Zhang H, Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82:488–499
Banerji U et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152–4161
Goetz MP et al (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078–1087
Grem JL et al (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885–1893
Ramanathan RK et al (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11:3385–3391
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216
Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F (2006) Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 5(5):1256–1264
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3
Chiosis G et al (2006) Hsp90 inhibitors—a chronicle from geldanamycin to today’s agents. Curr Opin Investig Drugs 6:534–541
Solit DB, Ivy SP, Kopil C et al (2007) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13(6):1775–1782
Roden DM (2004) Drug-induced prolongation of the QT interval. NEJM 350:1013–1022
Veerareddy PR, Vobalaboina V (2004) Lipid-based formulations of amphotericin B. Drugs Today (Barc) 40:133–145
Zamboni WC, Gervais AC, Egorin MJ et al (2004) Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53:329–336
Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133–141
Newman MS, Colbern GT, Working PK et al (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1–7
Working PK, Newman MS, Stuart Y et al (1994) Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in STEALTH liposomes. Liposome Res 46:667–687
Ewer MS, Martin FJ, Henderson C et al (2004) Cardiac safety of liposomal anthracyclines. Semin Oncol 31(suppl 13):161–181
Northfel DW (1994) STEALTH liposomal doxorubicin (SLD) delivers more DOX to AIDS-Kaposi’s sarcoma lesions than to normal skin. Proc Am Soc Clin Oncol 13:51
Rose PG (2005) Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10:205–214
Cattel L, Ceruti M, Dosio F (2004) From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother 16(suppl 4):94–97
Vail DM, Amantea MA, Colbern GT et al (2004) Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 31(suppl 13):16–35
Dragovich T et al (2005) Phase 1 study of CNF1010 (lipid formulation of 17- (allylamino)-17-demethoxygeldanamycin: 17-AAG). Clin Can Res 11:9117s
Ficker E, Denis AT, Wang L, Brown AM (2003) Role of the cytosolic chaperones Hsp70 and Hsp90 I maturation of the cardiac potassium channel hERG. Circ Res 92:e87–e100
Bhat RV, Engber TM, Zhu Y, Miller MS, Contreras PC (1997) Identification of insulin-like growth factor binding protein-2 as a biochemical surrogate marker for the in vivo effects of recombinant human insulin-like growth factor-1 in mice. J Pharmacol Exp Ther 281:522–530
Sandri MT, Johansson H, Colleoni M et al (2004) Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res 24:1261–1266
Maxwell P, van den Berg HW (1999) Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett 139:121–127
Chatterjee S, Park ES, Soloff MS (2004) Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol 11:876–884
Hayes DF, Yamauchi H, Broadwater G et al (2001) Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703–2711
Hunter-Lavin C, Davies EL, Bacelar MM et al (2004) Hsp70 release from peripheral blood mononuclear cells. Biochem Biophys Res Commun 324:511–517
Zhong L, Peng X, Hidalgo GE et al (2003) Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev 27:285–290
Acknowledgments
The study was funded by Biogen Idec Inc., San Diego, CA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saif, M.W., Erlichman, C., Dragovich, T. et al. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol 71, 1345–1355 (2013). https://doi.org/10.1007/s00280-013-2134-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-013-2134-9